Haematologica, Vol 92, Issue 9, 1286-1288 doi:10.3324/haematol.10680
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weingrill, E.
Right arrow Articles by Liebmann, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weingrill, E.
Right arrow Articles by Liebmann, P. M.

Chronic Lymphocytic Leukemia

Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients’ pretreatment status

Eva Weingrill*,°, Albert Wölfler*, Dirk Strunk*, Werner Linkesch*, Heinz Sill*, Peter M. Liebmann°,

* Division of Hematology, Department of Internal Medicine
° Institute of Pathophysiology, Medical University Graz, Austria

Correspondence: Peter M. Liebmann, PhD, Institute of Pathophysiology, Centre of Molecular Medicine, Medical University Graz, Heinrichstrasse 31a, 8010 Graz, Austria. Phone: international +43.316.3807676. Fax: international +43.316.3809640. E-mail: peter.liebmann{at}meduni-graz.at

Roscovitine induced apoptosis in isolated B-chronic lymphocytic leukemia cells of 25 patients of whom nine with relapsed and seven with fludarabine-refractory disease. It was synergistic with alemtuzumab and restored sensitivity to alemtuzumab in initially alemtuzumab-resistant samples. Observed roscovitine-induced up-regulation of CD52 surface expression may be one of the underlying mechanisms for this synergism.

Key words: B-CLL, roscovitine, alemtuzumab, apoptosis, synergism.